{
    "url_original": "https://www.wsj.com/articles/64x-bio-lands-55-million-for-gene-therapy-tech-11642595402?mod=markets_featst_pos3",
    "url": "64x-bio-lands-55-million-for-gene-therapy-tech-11642595402",
    "title": "64x Bio Lands $55 Million for Gene-Therapy Tech",
    "sub_head": "Startup seeks to improve efficiency of gene-therapy production",
    "time": "2022-01-19 07:30:00",
    "body": "Startup 64x Bio has secured $55 million in a financing round led by venture firm Lifeforce Capital to use its cell line-engineering technology to improve production of gene therapies now under development for a growing number of disorders.<br />The company aims to help drugmakers better produce viruses for gene therapies, which use non-disease-causing viruses to deliver healthy genes into cells of patients. The healthy genes compensate for missing or defective genes.<br />Drugmakers..."
}